BioPharma

The pharmaceutical sector has witnessed a significant shift toward the development of biologics, which now constitute a substantial portion of the global drug pipeline. Unlike small molecules, biologics are typically large, complex proteins that require parenteral administration due to...

The biopharmaceutical sector is currently navigating an era of unprecedented growth and technological complexity. As the global drug pipeline shifts toward advanced modalities such as cell and gene therapies, bispecific antibodies, and complex mRNA formulations, the demands placed on...

The transition from living cell therapies to cell free alternatives represents one of the most significant shifts in modern biotechnology. For years, the regenerative medicine sector has relied on the transplantation of whole cells to repair tissues and modulate...

We are currently standing at the threshold of a medical revolution, transitioning from a model of managing chronic conditions to one of potentially curing genetic diseases at their foundational level. The promise of advanced therapeutics such as CRISPR-based gene...

How advanced analytical methods, potency assays, and immune profiling are shaping the future of cancer cell therapies Cell therapies have transformed the treatment landscape for patients with cancer and other serious diseases. Innovations such as CAR-T cell therapies have demonstrated...

Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics...

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8...